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The study of the renal sites and mechanisms of action of
diuretics received a major boost by the experiments conducted
by the Dallas group in the mid and late sixties [1, 2]. Utilizing
clearance techniques and sharp,judicious analysis of free water
excretion (CH10) and reabsorption (T'H,o) curves, these inves-
tigators set the basis for the present knowledge of the nephron
sites of action and rational clinical use of diuretics. Micropunc-
ture and isolated tubule techniques proved most of the infer-
ences and general concepts developed from clearance method-
ology to be correct [3]. Moreover, clinical studies that aim to
assess the nephron sites of action of diuretics (and other drugs)
still depend on clearance methods for interpretation.
In the past two decades (70 and 80's) it has become possible
to examine in more detail many of the cellular and molecular
mechanisms of action of diuretics. These agents are one of the
remarkable achievements of the pharmaceutical industry. They
are efficacious, relatively innocuous and inexpensive drugs that
are life-saving in their short- (such as, in acute hypercalcemia or
hyponatremia [4, 5]) as well as in their long-term utilization
[6—8]. Most importantly, they are agents that interact with their
tissue targets in a reversible way that permits swift modification
of dosage and therapeutic goals. The targets for diuretic agents
are located along the different segments of the nephron. Po-
tency of these drugs—in practical terms, the degree of salt and
water losses they induce—depends precisely on which part of
the nephron they affect. Also, on the ancillary effects the agents
may exert on systemic and renal hemodynamics.
Recent reviews have emphasized the clinical use and phar-
macology of diuretics [9—11]. Therefore, our purpose is to
discuss renal tubule transport mechanisms, and the cellular and
molecular aspects of the interaction between diuretics and their
targets.
Epithelial transport in the principal nephron segments affected
by diuretics
Cellular elements in the kidney possess a rich array of
transport mechanisms which have been strategically localized
along the nephron to insure that the filtrate is converted into a
final product that allows homeostasis to prevail. Thus, under
normal circumstances, the role of these transport processes is
to guarantee that the volume and composition of extracellular
fluid, hence the intracellular milieu, remain unchanged.
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It has become apparent that diuretic agents may alter the
reabsorption of salts and water and the secretion of various
substances by interfering with one or more aspects of a given
transport system. Figure 1 schematizes the principal sites of salt
and water reabsorption along the nephron and the mechanisms
involved. A discussion of these follows.
Proximal tubule
The Na/H antiporter is the major mechanism responsible
for sodium entry into cells of the proximal convolution [121. The
antiporter is located in the apical (luminal) membrane and its
operation is dependent on favorable gradients for sodium (lu-
men-to-cell) and for protons (cell-to-lumen). The intracellular
pH is particularly critical. The gene for the Na/H exchanger
has been cloned and the predicted model for the membrane
model resembles that of the growing family of transporter
molecules [13; vide infra].
Two other important mechanisms determine the rate of
sodium transport in the proximal tubule. The basolateral cell-
membrane sodium pump (NaK-ATPase) is responsible for
maintaining cell sodium concentration approximately 1/10 of
that of the luminal fluid and blood. The pump consists of alpha
and beta subunits, both of which traverse the membrane [14;
vide infra]. Specific inhibitors of the pump (cardiac glycosides)
bind to the alpha subunit on the extracellular site, and while
some diuretics may lead to non-specific inhibition of the pump
[151, none do so at the concentrations used clinically. Needless
to say, specific or non-specific inhibition of the pump will lead
to diminished net sodium reabsorption by reducing the favor-
able lumen-to-cell sodium gradient thus impairing the function
of the Nat-proton antiporter.
Carbonic anhydrase is the other critical step in the generation
of the appropriate conditions for the functional integrity of
proximal tubule sodium reabsorption. Protons secreted in ex-
change for sodium are generated by the catalytic effect of the
enzyme on carbonic acid in the cell. Furthermore, protons
secreted into the lumen are buffered by bicarbonate in the
filtrate and the catalyzed dehydration of carbonic acid by
luminal (brush border) carbonic anhydrase [16]. Inhibitors of
carbonic anhydrase have so far been the only diuretics that
effectively inhibit proximal tubule sodium reabsorption. They
reduce the availability of intracellular protons and induce a
luminal acid disequilibrium pH, which impedes proton secre-
tion into the lumen.
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Fig. 1. Principal transport systems in various nephron segments. The main targets for diuretic action in each segment are indicated by the
appropriate symbol. The sodium-pump is indicated by ®; symports and antiports by 0; straight broken lines indicate conductive pathways. Details
on each segment are given in the text. The following are worth special attention: I) Proximal tubule basolateral NaIHCO3 co-transport, N = 3. 2)
Thick ascending limb luminal Na/H exchanger is under the control of aldosterone. The basolateral Na/HCO3 co-transport would be most evident
during activation of Na/H exchange.
Sodium reabsorption into the proximal tubule also proceeds None of these processes appear to be specifically inhibited by
coupled to phosphate, glucose, amino acids and other organic clinically useful diuretic doses.
anions. In addition, an electroneutral sodium-chloride reab-
sorptive process exists. This may be coupled to parallel sodium-
proton and chloride-bicarbonate exchange. Evidence also ex-
ists for a basolateral 1 Na/3 HC03 electrogenic symport [17].
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probably the case because its reabsorptive capacity is quite high
[18]. As a result, inhibition of proximal reabsorption is compen-
sated by high reabsorptive rates in the TAL and the net increase
in excretion is modest, poor or none. A complex luminal
electroneutral carrier seems to be responsible for the high
reabsorptive capacity of this segment. The carrier brings 1 Nat,
I K and 2 C1 into the cell with energy provided by the
basolateral activity of the Na,K-ATPase pump. Sodium
leaves the cell into the blood through the pump, but the fate of
chloride is varied. One chloride leaves the cell via an electro-
neutral KC1 symport; the other makes its exit through a
conductive chloride channel [19].
The activity of the apical membrane co-transporter aided by
the energy generated by the pump-induced sodium gradient
raises intracellular chloride and potassium activity above equi-
librium, which determines the chloride conductive exit. There
being no major potassium conductance across the basolateral
cell, it is recycled to the urine via the apical membrane, which
exhibits high K conductance. This recycling of potassium in
tandem with chloride exit is responsible for the lumen-positive
transepithelial potential that drives Na out of the lumen of the
TAL via a paracellular pathway. This mode of transport is
responsible for an equal number of sodium ions being trans-
ported passively through the paracellular space, and through
the co-transporter. In addition, the paracellular pathway is the
means of passive reabsorption for potassium, calcium and
magnesium.
Oberleithner and collaborators [20, 211 have advanced evi-
dence in support for Na/H antiport in the apical membrane of
the TAL. This urine acidification (cell alkalinization) process
and the enhanced apical K conductance is regulated by
aldosterone [221.
Distal convoluted tubule
An important regulator of final urine composition, the distal
convolution is principally characterized by a luminal electro-
neutral NaC1 symport [23]. The presence of the NaK-
ATPase and a sodium-calcium exchanger in the basolateral
membrane together with an apical barium-sensitive potassium
conductance impart the rest of the transport characteristics of
this segment. The possibility of an apical K-transport mecha-
nism, an outwardly directed (cell-to-lumen) potassium-chloride
co-transporter, and an apical potassium conductance has not
been conclusively proven.
Studies by Beaumont and collaborators [24] have suggested
that a thiazide binding site in isolated renal tubule membranes
may represent the NaC1 symport (vide infra).
Collecting duct
This is the final segment responsible for major modifications
in urine compositions in response to diuretics. In this nephron
site principal cells are the predominant cell type and responsible
for sodium reabsorption and potassium secretion [251. As in
most transporting cells the basolateral membrane NaKt
ATPase is responsible for transcellular sodium transport; this
site also presents potassium and chloride exit steps. The apical
membrane exhibits a putative KCI co-transporter, and signifi-
cant sodium and potassium conductances. The "small" sodium
conductance channels are of critical importance in establishing
the depolarization of the apical membrane which permits p0-
tassium secretion down a favorable electrochemical potential
gradient [26]. Of the two potassium channels (high and low
conductance) the low conductance seems to be responsible for
potassium secretion [27]. Finally, the intercalated (or mitochon-
drial rich) cell is responsible for hydrogen ion secretion and
potassium reabsorption. In states of potassium deprivation an
ATP-dependent K-H exchanger in the apical membrane may be
responsible for potassium reabsorption and a portion of H
secretion (the remainder H secretion is electrogenic). The
functional capacity of this exchanger mechanism is not as great
under normal conditions. Evidence has been advanced that this
ouabain-insensitive K-stimulated ATPase can be blocked by
K-H inhibitors [28].
Cellular and molecular aspects of transport systems affected by
diuretics
Carbonic anhydrase
This enzyme is found in the cytosol of the renal tubular cells
as a high-activity form called CA II. "High activity" refers to
its capacity to hydrate CO2 and dehydrate H2C03, and the form
and function of this isoenzyme is identical to that of the CA II
of erythrocytes [29]. The other cytosolic isoenzymes described,
CA I and CA III, are found in erythrocytes and skeletal muscle
respectively, but are not present in the kidney [30]. Recently it
has been demonstrated that the carbonic anhydrase activity in
microvilli and basal infoldings of renal tubular cells from human
kidneys is associated with a strongly membrane-bound enzyme
protein. Provisionally called CA IV, this protein seems to be
different from the cytoplasmic soluble forms of the enzyme, but
it is the type of carbonic anhydrase responsible for the reab-
sorption of bicarbonate in the proximal tubule [31].
Purification to homogeneity has revealed CA IV to have a
molecular weight between 34.4 and 36.7 kDa. Kinetically the
enzyme was similar to CA II with respect to hydrase and
esterase activities and to inhibition by various sulfonamides.
When CA IV is reconstituted into lipid bilayer membranes, it
forms channels selective for small cations [32]. The physiolog-
ical significance of this finding, however, is presently obscure.
Membrane associated carbonic anhydrase proteins have been
isolated from rat brain myelin (44 kDa) and bovine lung (42
kDa), but it remains to be shown whether membrane isoen-
zymes are homologous even though localized in different tis-
sues [31, 33].
The genes of several isoenzymes, including CA II, have been
cloned [341. In the chick brain in situ hybridization has revealed
CA II mRNA most intensely in the choroid plexus and in
neurons [35]. In addition to its presence in the brain in a
structure responsible for fluid and electrolyte transport (the
choroid plexus), CA II mRNA levels are induced in parietal
cells by carbachol, histamine and gastrin, three of the most
potent stimulants of gastric acid secretion [36]. In the syndrome
of osteopetrosis and renal tubular acidosis, it has been shown
that affected individuals lack CA II in erythrocytes [37]. More-
over, in an animal model for this syndrome, lack of paternal CA
II has been demonstrated to be heritable and due to a null
mutation at the Car-2 locus on chromosome 3 [38]. Studies of
gene expression in the kidney may reveal important information
as to the ontogeny and regulation of this critical enzyme in
acid-base regulation and, perhaps, of differences induced by
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chronic states in which diuretic inhibitors of the enzyme are
required.
The sodium-hydrogen antiport
The principal properties of this plasma membrane-bound
protein include the following: 1) electroneutrality; it exchanges
Na or Li for H with a coupling ratio of 1:1; 2) in membrane
vesicles or in intact cells an inward-directed Na gradient
drives uphill H effiux and an outward-directed Na gradient
drives uphill H influx, thus the transporter is reversible; 3)
H, Na, Li and amiloride all compete for an external binding
site in the transporter; 4) H binding to an internal regulatory
site exerts an allosteric activation, thus acting as a self-con-
trolled H efflux pathway [reviewed in 39, 40]. Intracellular pH
is critical in the control of the transporter; when it rises >7.4 the
mechanism comes to a virtual halt, whereas it is activated at
low pH with maximal effects detected at pH 6. Numerous
growth factors and growth promoting agents (platelet-derived
growth factor or PDGF; epidermal growth factor or EGF;
fibroblast growth factor or FGF; serum, alpha thrombin, vaso-
pressin, bradykinin, phorbol esters, concanavalin A) stimulate
the Na/H exchanger by apparently increasing the affinity of
the internal modifier site. The relationship of this finding to
sodium transport in renal tubule has not been explored [41].
Equally mysterious is the role of second messengers in
activation of the antiporter in relation to renal tubule function.
Growth factors and other growth promoters activate the hydrol-
ysis of phosphoinositides (PIP2) leading to the formation of
inositol trisphosphate (1P3) and diacylglycerol. Phospholipase C
activation is transduced from the membrane receptors via a
GTP-binding protein. The rise in intracellular calcium produced
is not sufficient to trigger a pH change, therefore, activation is
most likely via protein kinase C. In contrast, EGF, and perhaps
FGF, may stimulate the antiporter by activating the tyrosine
kinase activity of their respective receptors leading to phos-
phorylation of the exchanger [421.
The Na/H exchanger bears some topological similarities to
the adrenoceptor molecule. Amiloride, an inhibitor of the
Na/H exchanger, has only very moderate diuretic potency.
Interestingly, it also binds to, and antagonizes, alpha and beta
adrenoceptors (alpha2> alpha1 > beta) even at concentrations
below those required to inhibit the exchanger [43]. Stimulation
of the alpha2 adrenoceptors activates the Na/H exchanger
suggesting that catecholamines may be involved in this way in
the regulation of sodium reabsorption in the proximal tubule
[44]. It seems unlikely, however, that an interaction of amilo-
ride to block adrenoceptors plays a major role at clinically
useful doses of the diuretic.
The sequence of a cDNA encoding the human amiloride-
sensitive Na/H antiporter has been presented [13]. The
cDNA includes a non-coding leader of 407 bp, a 2682 bp open
reading frame, and a 3' noncoding sequence. The amino acid
sequence predicts a protein of Mr = 99,354 with an N-terminal
amphiphatic domain that contains 10 putative transmembrane-
spanning segments and two-potential glycosylation sites, fol-
lowed by a hydrophilic stretch of 395 residues, presumably
cytoplasmic. The number of putative transmembrane segments
are reminiscent of the CIHCO3 antiporter.
The NaKt2Cl co-transporter
A thorough review of the mechanistic details of this transport
system is beyond the scope of this article [for recent reviews
see 45, 46], but its major characteristics are given below.
It is essential for identification of this system that it be
inhibited by loop diuretics (bumetanide, furosemide, piret-
anide). There is absolute requirement of two of the ions for
transport of the third ion (for example, Na and Cl must be
present for K reabsorption to proceed) and it is always electro-
neutral. Therefore, ion translocation does not alter membrane
potential nor does membrane potential affect transport of cou-
pled ions. The stoichiometry of the coupling of ions is very tight
and driven by the third ion (such as, K flux-Nat flux, driven
by C1 gradient). Some of the participating ions can be substi-
tuted in a restricted way, for example Li for Na, Rb or
NH4 for K, Br for C1. Since net ion movement is
energized by the ion gradients, there is no direct requirement of
ATP hydrolysis for transport. Finally, since the direction of
transport is governed by the algebraic sums of the electrochem-
ical gradients of each of the three ions, net transport is
reversible.
It has been observed that in isolated TAL preparations with
preformed ion gradients, which do not require energy from
ATP, ATP enhances the activity of the co-transporter. Further-
more ATP utilization and transport rates bear little relation
under these circumstances. In addition, activation of the Na-
K-2Cl co-transporter leads to membrane protein phosphor-
ylation, suggesting that phosphorylation of the co-transporter
by protein kinases facilitates ion binding and translocation [47].
Utilization of [3H]4-benzoyi-5-sulfamoyl-3-(3-thenyloxy) ben-
zoic acid (BSTBA), which contains a photoreactive benzophe-
none group, is a potent ioop diuretic and competes with its
analogue bumetanide for binding sites on dog renal membranes,
has permitted the identification of specific photoincorporation
of the molecule to a dog kidney protein of approximately 150
kDa [48]. This same group found that when the dog kidney
membranes were incubated in media containing Na, K, Cl and
0.2 M [3H]bumetanide, incorporation of the label resulted in
the —-40 kDa region but not in the 150 kDa [49]. Inhibition of the
labeling, however, was less than 50% when unlabeled bumet-
anide was added to the medium, suggesting that the labeled
protein(s) are not part of the Na-K-2Cl co-transporter. Most
likely they are low affinity bumetanide binding sites such as the
basolateral K-Cl cotransport system of the TAL or other
transport proteins. In addition, dog kidney membrane proteins
of variable molecular weight that incorporate [3H]BSTBA with
low affinity, have also been detected [50]. Radiation inactiva-
tion studies in rabbit kidney TAL membrane vesicles led Kinne
and co-workers to report a 80 to 90 kDa apparent molecular
weight for the Na-K-2C1 co-transporter [511.
Evidently, the nature of the protein or protein complex that
makes up the co-transporter is not clear. The number of
proteins reported raises the question of whether all of them
could represent components of the cotransporter, but identifi-
cation of its structure in TAL remains to be elucidated.
The Na-Cl symport
The early distal tubule (we use the term to signify the earliest
portion accessible to micropuncture, that is distal to the macula
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Table 1. Inhibition of [3H1 metolazone binding to the high affinity
site of rat kidney membrane fractions by some thiazide-type diuretics
Drug
K,,
nM
Methychlothiazide
Metolazone
Indapamide
Hydroflumethiazidea
Hydrochlorothiazide
Chlorothiazide
0.43
5. 1
29
43
146
3630
This Table is adapted from Beaumont et al [24].
Selectively inhibits high affinity site
densa and ends before connecting and collecting tubule) is
residence for a rather unique cotransport system for Na and K,
that seems to have an exact replica in the urinary bladder of the
winter flounder [52]. The symport is not affected by mucosal
K concentration: neither sodium or chloride transport are
affected [53]. Net fluxes of Na and Cl are identical and com-
pletely interdependent (reduction of one inhibits transport of
the other). Thus, it is clear that this system, in contrast to the
TAL Na-K-2C1 cotransporter, is K-independent. Moreover, Na
transport is not affected by amiloride in doses as high as 15 mM,
nor is chloride reabsorption inhibited by the disulfonic stilbene,
DIDS, indicating that neither Na/H exchange nor Cl/base
exchange determine its operation. The system is not antago-
nized by carbonic anhydrase inhibitors and insensitive to bu-
metanide. The former eliminates the possibility of parallel
synchronous antiporters, the latter that the system is analogous
to that in the TAL [54}.
On the other hand, furosemide partially inhibits Na-Cl sym-
port, while thiazides and metolazone completely halt its func-
tion [55]. Of interest is that thiazide-like drugs, including
metolazone, have no effect on TAL function [56, 57]. Still to be
elucidated and fully understood is the significance of the partial
furosemide effect (which also occurs in the bladder of the winter
flounder).
Two important aspects of the symporter in relation to diuret-
ics are its effects on calcium reabsorption and potassium
secretion. It has been shown that thiazides increase calcium
reabsorption both in the early distal tubule and in the winter
flounder bladder [58, 591. While the mechanism for this effect is
not well understood, it is possible that hyperpolarization of the
mucosal membrane by the diuretics could increase calcium
entry into the cell through calcium channels [52]. In addition,
reduction in the apical reabsorption of NaCl could lead to
partial inhibition of the Na-pump. Influx of sodium from blood
to cell could activate a Na/Ca21 exchanger which would
effect increased net transcellular reabsorption in the presence of
enhanced apical Ca entry.
Of particular interest is the capacity for potassium secretion
afforded by the co-existence of apical NaCl and KCI cotrans-
porters in the early distal tubule. Increasing luminal chloride
concentration should increase the reabsorption of both ions.
The enhanced lumen-to-cell sodium movement will increase the
activity of the contraluminal ATPase and lead to increased cell
K and thus, because of the favorable cell-to-lumen gradient,
increased K secretion [60]. This mechanism may be respon-
sible for the potassium losses seen in loop diuretic administra-
Table 2. Some compounds that compete for the low affinity [3H]
metolazone binding site of rat kidney membranes
K,,
Compound 1.M
Metolazone 0.26
Nicardipine 0.62
Nitrendipine 0.65
Verapamil 1.2
Diltiazem 5.8
Nifedipine 15
This Table is adapted from Beaumont et al L241.
tion and in metabolic alkalosis. In the former, increased C1
presentation to the NaCl symport would activate K secretion,
as has already been discussed. In the latter, the increased
luminal bicarbonate or increased sodium (or both) in the early
distal tubule would create differences in luminal Na and C1
concentrations, poising the epithelium for K secretion.
The thiazide receptor
Studies using metolazone, a quinazoline-sulfonamide which
differs from the sulfonamide diuretics in the benzothiadiazine-
dioxide ring [61], by Beaumont, Vaughn and Fanestil [24] have
indicated the presence of [3H] metolazone receptors in a
preparation of rat kidney cortical membranes. Ten percent of
the total binding of [3H] metolazone was to carbonic anhydrase,
but two [SI-I] metolazone binding sites were identified: a high
affinity (Kd = 4.27 0.37 nM, Bmax = 0.717 0.058 pmol/mg
protein) and a low affinity (Kd = 289 43 M, = 3.92
0.36 pmol/mg protein). Binding to the high affinity site was
limited to thiazide-like compounds, whereas several non-thia-
zides and thiazide-like compounds inhibited binding of [3H]
metolazone to the low affinity site (Tables 1 and 2). Metolazone
was the most potent inhibitor of the low affinity site. Various
classes of calcium channel antagonists also inhibited this site
(Table 2) Nicardipine (10— M) when added to membrane
preparations prevented [3H] metolazone binding to the low
affinity site.
There was a significant correlation between the pharmaco-
logic potency of the thiazide-like diuretics and their affinity for
the high affinity [HI metolazone binding sites in rat kidney.
Of several tissues examined, the kidney cortex had the
highest density of both the high and low affinity binding sites.
Chloride, bromide, and iodide (100 mM) inhibited the high
affinity binding site more than 50%, suggesting that these halide
anions compete with metolazone for a transport site or channel.
In another set of studies with the same preparation, Tran,
Beaumont and Fanestil [62] found that sodium increases the
affinity of [3H] metolazone for the binding site from Kd = 3.56
0.15 flM to Kd = 1.32 0.1 n. Chloride, in the presence of
50 mM, Na, competitively inhibited [3H] metolazone binding
by suppressing the affinity (Kd = 9.27 1.11 nM). The maximal
number of binding sites remained unchanged (Bmax = 0.733
0.049 pmol/mg protein. These investigators proposed that the
transporter (receptor) possess sites for Na and C1, and
metolazone binds to the C1 site. Moreover, Na binding
increases the affinity of Cl and metolazone to their common
site in the transporter. The co-dependency of sodium and
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Table 3. Effect of ischemia reperfusion on the affinity and binding
site density of the high affinity [3H] metolazone receptor of rat kidney
membranes
B max
Condition
pmollmg
protein
Kd
nM
Control 0.555 0.052 2.91 0.18
Ischemic (10 mm) 0.058 o.ola 6.70 2.62
Ischemic (10 mm) 0.347 0.086 2.37 0.34
+ reperfusion (10 mm)
This Table is adapted from Beaumont et al [64].
N = 3 to 5.
a P < 0.001 vs. control
chloride in the salt reabsorptive processes of the rat distal
tubule has already been alluded to above.
Using autoradiographic analysis of rat kidney sections previ-
ously incubated with [3H] metolazone, Beaumont and associ-
ates [63] detected a preferential binding of [3HJ metolazone to
the early distal convoluted tubule. Labeling was more promi-
nent in the luminal than the peritubular site. Medullary struc-
tures remained unlabeled. Interestingly, not all the cells of the
distal tubules were labeled, confirming that more than one cell
type is present in that segment. The absence of labeling in the
proximal tubule reinforced the notion that thiazide actions in
the segment are secondary to carbonic anhydrase inhibition.
Beaumont et al [64] looked into the regulation of the thiazide
receptor during renal ischemia. Clamping of the renal artery for
10 minutes resulted in a significant reduction in [3H] metolazone
sites (Table 3). Reperfusion for another 10 minutes increased
receptor binding sites significantly, although it did not reach
baseline values. Receptor affinity constants remained unal-
tered.
Incubation of rat cortical tissue under oxygen (02) or nitrogen
(N2) atmosphere at 37°C resulted in a significant decrease in
[3HJ metolazone receptor density, being more prominent with
N2. Addition of mitochondrial inhibitors (dinitrophenol, rote-
none), but not ouabain, further reduced receptor density in the
oxygenated tissue sections. Since the reduction in [3H] meto-
lazone receptor binding density in kidney tissue (02 or N2
atmosphere at 37°C for 10 mm) was not observed in membrane
preparations, the authors suggested that changes in intracellular
sodium or reductions in membrane potential are involved in the
down regulation of the thiazide receptor in these experimental
conditions.
Finally, the same group of investigators [65] measured [3H]
metolazone receptor density and binding affinity in a model of
genetically determined hypertension, the spontaneously hyper-
tensive rat (SHR). SHRs (15 weeks old) had significant incre-
ments in thiazide receptor density when compared to age-
matched Wistar-Kyoto rats (WKY) (SHR: Bmax = 0.452
0.021 vs. WKY: Bmax = 0.375 0.020 pmol/mg protein; P <
0.05).
On the other hand, hypertension produced by placing a clip in
a renal artery of normal rats (2K-IC model) did not result in
significant alterations in thiazide receptor density in either
kidney (clipped, Bmax = 0.467 0.033 vs. unclipped, Bmax =
0,495 0.028 pmol/mg protein) [66]. Further studies are nec-
essary to elucidate if the rise in thiazide receptor density
antedates or is coincidental with the rise in blood pressure in the
SHR model.
The clinical correlates of the studies during ischemia and
hypoxia, and the SHR are clearly acute renal failure and low
renin hypertension. It would be mere speculation to transpose
these findings to the clinical setting at the present time, but
these studies could set the base for elucidation of the in vivo
responses of the ischemic kidney to thiazides (and other diuret-
ics), and of the antihypertensive effects of thiazides in various
forms of hypertension.
The relationship between the thiazide receptor and the NaCI
co-transporter remains to be elucidated, but it seems that
thiazide-binding sites may represent, if not the transporter
itself, part of its component proteins.
Amiloride-sensitive sodium channels
A voltage-independent, sodium-specific ion channel that is
sensitive to the potassium-sparing diuretic amiloride has been
found only in transporting epithelia [reviewed in 67]. The
preferential inhibition by amiloride exhibits high affinity, with
an apparent equilibrium dissociation constant (K1) of less than 1
/LM. Located primarily in the apical membrane of epithelia, it is
involved in transepithelial sodium transport. In addition, it is
hormonally regulated [68]. The channel is critical in permitting
the entry of sodium into the cells of the renal tubule, and it is
rate limiting for the ATPase sodium-pump. Thus, it may well be
the single most important step in determining sodium and water
balance in the body. Despite this, the only nephron site in which
it may be vulnerable to diuretic action, is the collecting tubule,
thus we will limit our comments to this structure and refer the
reader to Benos's excellent review [67].
Two fundamental criteria that must be met in any attempt to
purify the sodium channel are that the probe that binds to the
channel protein does so with high affinity, and that the transport
function of the protein be maintained at every step of the
procedure. To this end, the use of the high-affinity amiloride
analogue [3H]-methylbromoamiloride and transport function
retention at every step has permitted reconstitution into planar
bilayers of amiloride-sensitive single sodium channel activity
[69].
Table 4 summarizes some of the present knowledge concern-
ing the characterization of sodium channel proteins. The native
sodium channel consists of a heterohexameric complex of
subunits, ranging in molecular size from 40 to 300 kDa. In the
non-reduced state the complex runs as a single band of 730 kDa,
suggesting that the various subunits, of weights indicated in the
table, are covalently attached to each other by disulfide bridges.
Under non-reducing conditions, [3H]-methylbromoamiloride
binds to a component of bovine renal papillary homogenate
with an apparent molecular mass of 730 kDa, while under
reduced conditions the binding protein is 150 kDa. Both of these
proteins are part of the purified epithelial sodium channel
preparation and most likely represent the amiloride binding
subunit. Reports of multiple polypeptides from bovine kidney
that can bind a high affinity analogue of amiloride have opened
the question of multiple binding sites versus degradation prod-
ucts of the larger molecule [70]. It should be mentioned that, as
is the case with other transport proteins, these are glycosylated,
and all can be phosphorylated by cyclic AMP-dependent pro-
tein kinase [71].
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Table 4. Molecular mass ratios of amiloride-binding and epithelial
Na channel proteins from different tissues
Native Subunit
molecular molecular
mass mass
Source Method kDa kDa
Rat kidney Radiation 650
cortex inactivation
Pig kidney Radiation 185 90—105 (dimer)
cortex inactivation/3H-
phenamil
binding
A6 cells, 3H-methyl- 730 300
bovine renal bromoamiloride ISO
papilla binding 95
0
55
40
This Table is adapted from Benos [67].
The dimer (two identical subunits of 90 to 105 kDa) discov-
ered in pig kidney cortex, which also is a putative amiloride-
sensitive sodium channel, may not be the same as the high
amiloride-affinity epithelial sodium channel. Its kinetics indi-
cate that it may represent a low amiloride-affinity sodium
conductive pathway sometimes observed in vesicle uptake
experiments and in basolateral membranes of some epithelia
[721.
Use of monoclonal and polyclonal antibodies against the
purified amiloride-sensitive sodium channel protein have per-
mitted the identification of single amiloride-sensitive sodium
channels in rat renal medullary collecting ducts. Staining of the
channels is circumscribed to the apical membrane of principal
cells, whereas the intercalated cells are unlabeled [67].
In view of the binding site of amiloride in the epithelial
channel it seems certain that the diuretic effect of this agent is
a result thereof.
Spirolactones: Mineralocorticoid receptor antagonists
The discovery of a group of steroid-related compounds with
corticosteroid blocking actions in the late 1950's has helped to
define the mechanisms by which corticosteroids modulate in-
tracellular events and transport processes in the kidney and
other tissues [73, 74]. There are two possible mechanisms to
explain the antimineralocorticoid actions of the spirolactones,
and in particular, spironolactone: a direct effect on aldosterone
synthesis by the adrenal gland, and inactivation of the mm-
eralocorticoid receptor in target tissue by competition with the
agonists (aldosterone) at the receptor site. Most of the experi-
mental evidence to date favor the latter mechanism as the
predominant one, although there is data supporting an effect in
adrenal steroid synthesis.
Erbler [75] found that spironolactone (l0— to l0 M)
decreased the synthesis of aldosterone by adrenal tissue ob-
tained from sodium depleted rats. There was a dose dependent
inhibition of dybutiryl cAMP (10—i M), ACTH, potassium and
angiotensin 11-stimulated aldosterone production. The concen-
trations of spironolactone necessary to achieve the inhibitory
effect in vitro were higher than those needed to inhibit sodium
transport in the toad bladder preparation [76, 77], suggesting
that the actions of the antagonist at the receptor level are of
critical importance for the overall in vivo effect.
Spironolactone, canrenone and canreonate-K inhibit 1 1-hy-
droxylase and l8-hydroxylase, and binds to cytochrome P450
[78]. Moreover, some of the thio-derivatives of spironolactone,
after undergoing further metabolism, are able to destroy cy-
tochrome P450 and its apoproteins [79, 80].
Nevertheless, in a recent review [81], Fanestil concludes that
these inhibitory actions of spirolactones on aldosterone synthe-
sis play a minor role in the overall antimineralocorticoid effects
of these compounds. The most important mechanism of action
is, then, on the mineralocorticoid receptor (MR) in target
tissues.
Spirolactones displace [3H] aldosterone from its specific
receptor in vitro [82—85]. Furthermore, after binding to the MR
the spirolactone-MR complex is unable to bind to the nuclear
acceptor sites or the hormone responsive elements (HRE's)
[86]. The affinity of spironolactones for the MR is lower than
that of aldosterone. Wambach and Casals-Stenzel [851 com-
pared the relative affinity of various spironolactone derivatives
to rat cytosolic [3H] aldosterone binding sites, and it was 10% of
that of aldosterone. They also described that the 17-spirolac-
tone ring is necessary for binding to the MR, as reported by
other investigators [82, 87]. It is possible that in vivo activation
of some of the spirolactones with closure of the spirolactone
ring results in higher in vivo activity than the one detected in in
vitro systems.
The MR has been recognized as the spironotactone binding
moiety in the mineralocorticoid target cells. Some recent data
dispute this conclusion. Luzzani and Glasser [88] looked at [3H]
spironolactone and [3H] aldosterone binding to kidney homoge-
nates of adrenalectomized rats. Specific [3H] spironolactone
binding was of high affinity and low capacity (Kd = 12.9 0.6
nM; Bmax = 93.4 3.8 fmol/mg protein). They also found that
[3H] spironolactone was displaced preferentially from its recep-
tor by spironolactone > prorenone > methyltrienolone, testos-
terone, progesterone, aldosterone  estradiol 17, dexametha-
sone. [3H] aldosterone was displaced by aldosterone >
dexamethasone > progesterone, spironolactone, prorenone >
testosterone. The spironolactone binding site had low sensitiv-
ity to aldosterone and did not bind dexamethasone. Since there
were differences in the binding characteristics, hormone spec-
ificities and thermal stability between the classic MR and the
spironolactone binding site, these authors conclude that this
site is distinct from the MR. The preliminary work of Lazar and
Agarwal [89] using a 7-alpha-propyl derivative of spirolactone
support this conclusion.
Previous studies employing [3H] spironolactone (SC 26304)
[86] and [3H] prorenone [84] support that these antimineralo-
corticoids compete with aldosterone for the same receptor.
Marver et al [86] found that [3H] aldosterone and [3H] SC
26304-receptor complex did not bind to nuclei or chromatin
whereas the [3H] aldosterone receptor complexes did bind.
Similar findings were obtained in kidney homogenates with [3H]
prorenone by Claire et al [84]. These studies corroborated the
finding of early studies by Fanestil [90] in the adrenalectomized
rat.
All these data point to the MR as the common site of the
agonist and antagonistic actions of these steroid related com-
pounds. The post-binding events of these agonist-MR or antag-
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Arriza and co-workers [97] were able to clone the human
mineralocorticoid receptor. There is a 94% homology of the
amino acid sequence of the DNA binding domain with the
human GR and 57% homology in the carboxy terminus (the
hormone binding site). Additional studies are necessary to
elucidate the reasons that the antagonist-MR complex is unable
to interact with the mineralocorticoid responsive elements in
the nucleus. It is possible that a process similar to that of the
antagonist-PR complex is involved.
The PR is composed of the hormone binding site, a non-
steroid, non-DNA binding protein (the 90 Kd heat shock protein
or hsp 90), and a nuclear protein (p59) [95]. When the agonist is
absent or when an antagonist binds to the hormone binding site,
the hsp 90 remains attached to the hormone receptor so the
DNA binding domain (which is part of the hormone or ligand
binding domain) is not exposed and does not interact with the
hormone responsive elements in the DNA. Agonist binding, on
the other hand, results in a conformational change of the
hormone binding domain that triggers the dissociation of hsp 90
from the receptor-agonist complex and exposes the DNA
binding site which interacts with the specific hormone respon-
sive elements. Transcription by RNA polymerase can then be
initiated.
Clearly, while competitive antagonism of aldosterone-recep-
tor binding by spironolactone is necessary for its potassium-
sparing and diuretic effects, the post-receptor effects responsi-
ble for its pharmacological action remain to be elucidated.
Summary
In the past few years, increased knowledge of the nature of
transport proteins and their molecular regulation in the trans-
location of ions across kidney membranes has emerged. We are
beginning to better understand the characteristics of the inter-
action of diuretics with these transport proteins. It is likely that
this knowledge will permit further insight into nephron function
regulation.
Reprint requests to Manuel Martinez-Maldonado, Department of
Medicine, Emory University Medical School, DVA Medical Center,
1670 Clairmont Rd., Decatur, Georgia 30033, USA.
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